Curious, how are they testing their phase 1B for AML with PXT-200? What read-outs are they looking at?
Think the story of personalized medicine for ATK pathways is nice. ROH and RAS mutations are common enough in the cancer lines they're targetting. They should be able to hit significant results if they have shown that PTX-200 can target such mutations and consequently reduce proliferation, apoptosis.... ATK pathways are well studied. MTOR activation also in cancer lines.
Phase 1b results are my major interest, gets exponentially more difficult to get a bio-play across the line after that. Especially in the oncology end. My thoughts.
Seems like there is a bit of time before results are due, mind you... late september / early october? right?
Cheers,
M
- Forums
- ASX - By Stock
- PTX
- Ann: June 2019 Appendix 4C - Quarterly
Ann: June 2019 Appendix 4C - Quarterly, page-70
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.7¢ |
Change
0.003(6.82%) |
Mkt cap ! $37.85M |
Open | High | Low | Value | Volume |
4.3¢ | 4.7¢ | 4.3¢ | $9.836K | 218.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 291891 | 4.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.7¢ | 59540 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 291891 | 0.043 |
5 | 387657 | 0.042 |
8 | 794000 | 0.041 |
12 | 1287734 | 0.040 |
2 | 210000 | 0.039 |
Price($) | Vol. | No. |
---|---|---|
0.047 | 59540 | 2 |
0.048 | 12664 | 2 |
0.049 | 72464 | 2 |
0.050 | 140000 | 2 |
0.051 | 277227 | 2 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |